PTC 299

Drug Profile

PTC 299

Alternative Names: PTC299

Latest Information Update: 11 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PTC Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer; CNS cancer; Neurofibromatoses; Solid tumours
  • Discontinued Kaposi's sarcoma

Most Recent Events

  • 27 Jan 2015 No development reported - Phase-I for Solid tumours (Combination therapy) in USA (PO)
  • 27 Jan 2015 No development reported - Phase-I/II for Breast cancer (Combination therapy, Metastatic disease) in USA (PO)
  • 27 Jan 2015 No development reported - Phase-II for CNS cancer (In children) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top